Department of General Pediatrics, Division of Inborn Metabolic Diseases, University Children's Hospital Heidelberg, Im Neuenheimer Feld 430, D-69120, Heidelberg, Germany.
Department of Metabolism, Children's Hospital, Hacettepe University Ankara, Ankara, Turkey.
J Inherit Metab Dis. 2009 Oct;32(5):630. doi: 10.1007/s10545-009-1189-6. Epub 2009 Jul 31.
Objectives Isolated methylmalonic acidurias (MMAurias) are caused by deficiency of methylmalonyl-CoA mutase or by defects in the synthesis of its cofactor 5'-deoxyadenosylcobalamin. The aim of this study was to evaluate which parameters best predicted the long-term outcome. Methods Standardized questionnaires were sent to 20 European metabolic centres asking for age at diagnosis, birth decade, diagnostic work-up, cobalamin responsiveness, enzymatic subgroup (mut(0), mut(-), cblA, cblB) and different aspects of long-term outcome. Results 273 patients were included. Neonatal onset of the disease was associated with increased mortality rate, high frequency of developmental delay, and severe handicap. Cobalamin non-responsive patients with neonatal onset born in the 1970s and 1980s had a particularly poor outcome. A more favourable outcome was found in patients with late onset of symptoms, especially when cobalamin responsive or classified as mut(-). Prevention of neonatal crises in pre-symptomatically diagnosed newborns was identified as a protective factor concerning handicap. Chronic renal failure manifested earlier in mut(0) patients than in other enzymatic subgroups. Conclusion Outcome in MMAurias is best predicted by the enzymatic subgroup, cobalamin responsiveness, age at onset and birth decade. The prognosis is still unfavourable in patients with neonatal metabolic crises and non-responsiveness to cobalamin, in particular mut(0) patients.
孤立性甲基丙二酸血症(MMAuria)由甲基丙二酰辅酶 A 变位酶缺乏或其辅因子 5'-脱氧腺苷钴胺素合成缺陷引起。本研究旨在评估哪些参数能最好地预测长期预后。
向 20 个欧洲代谢中心发送标准化问卷,询问诊断时的年龄、出生年代、诊断工作、钴胺素反应性、酶亚组(mut(0)、mut(-)、cblA、cblB)和长期预后的不同方面。
共纳入 273 例患者。疾病的新生儿期起病与死亡率增加、发育迟缓发生率高和严重残疾有关。新生儿期起病且钴胺素无反应的患者,若出生于 20 世纪 70 年代和 80 年代,则预后特别差。症状出现较晚的患者预后较好,尤其是钴胺素反应性或归类为 mut(-)的患者。在无症状诊断的新生儿中预防新生儿危象被认为是减少残疾的保护因素。mut(0)患者比其他酶亚组更早出现慢性肾衰竭。
MMAuria 的预后最好由酶亚组、钴胺素反应性、发病年龄和出生年代来预测。对于有新生儿代谢危象和对钴胺素无反应的患者,尤其是 mut(0)患者,预后仍然不佳。